er faster 
and better solutions to our customers. Were proud to be 
the first globally with this dual-modality configuration, located strategically in central Taiwan. Our partnership 
with IBAs Proton Therapy, Dosimetry, and Industrial 
Business Units has been enriching. Theyre an innovative 
company, and we have proudly collaborated with them. Michael Lee, Managing Director at CHC Healthcare Group 
14
IBA
CORPORATE BROCHURE 2024